Comparing the current results to its competitors, Xeris Biopharma Holdings Inc reported Revenue increase in the 1 quarter 2026 by 38.27 % year on year. The revenue growth was below Xeris Biopharma Holdings Inc 's competitors' average revenue growth of 83.6 %, achieved in the same quarter.
Xeris Biopharma Holdings Inc 's Comment on Competition and Industry Peers
The company operates in a competitive industry focused on proprietary products. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies with greater financial, technical, and human resources, as well as more experience in product development, regulatory approvals, and commercialization. In the treatment of endogenous Cushing’s syndrome, the company competes with Korlym (mifepristone), marketed by Corcept Therapeutics, which is indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance.
July 3, 2024
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a dynamic biopharmaceutical company dedicated to enhancing patient lives through the development and commercialization of groundbreaking therapies, has recently made a significant announcement that underlines its commitment to attracting top talent and fostering innovation. On July 1, 2024, Xeris revealed that the Compensation Committee of its Board of Directors has granted restricted stock units (RSUs) for an aggregate of 196,000 shares of its common stock to 26 new employees under the Xeris Inducement Equity Plan. These inducement grants were made in accordance with NASDAQ Listing Rule 5635(c)(4), which facilitates the recruitment of new employees by offering ...
Publicly Traded Peers of Xeris Biopharma Holdings Inc
Hoth Therapeutics Inc Share Performance
-15.86%
One Year
Hoth Therapeutics Inc
Profile
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Liquidia Corporation is a biopharmaceutical company that develops and commercializes products using its proprietary PRINT® technology to design and produce precision-engineered medicines. The company focuses on creating therapies for respiratory diseases and other areas of high unmet medical need, leveraging the potential of its unique particle engineering platform.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Xeris Biopharma Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xeris Biopharma Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
